Written questions by Charalambous.

What assessment he has made of whether funding for epilepsy research is proportionate to the prevalence of epilepsy.

Awaiting answer.

Whether his Department plans to increase funding opportunities for epilepsy research.

Awaiting answer.

What assessment he has made of the effectiveness of how dementia is reflected within NHS Continuing Healthcare eligibility criteria; and whether he plans to review the eligibility criteria as a result of the findings of the Casey Commission.

Awaiting answer.

How many people diagnosed with dementia have their Advance Care Plan reviewed in the last a) 12 month b) 24 months.

Awaiting answer.

What assessments he has made of trends in the level of regional variations in access to Advanced Care Planning for people living with dementia.

Awaiting answer.

Whether the Department has assessed the potential impact on the NHS in winter 2026-27 of providing the shingles vaccination programme to adults aged 80 in April 2027; and whether it has considered launching the programme in autumn 2026 alongside the seasonal flu and COVID-19 vaccination campaigns.

In November 2024, the Joint Committee on Vaccination and Immunisation (JCVI) provided advice on eligibility for the shingles vaccination programme for adults aged 80 years old and over. The Government continues to carefully consider the JCVI’s advice.We are taking key steps to ensure the National Health Service is prepared for the colder months. This winter, approximately half a million more people were vaccinated against flu compared to the previous season, though we know there is further to go next winter. We are undertaking a comprehensive ‘lessons learned’ review to help us identify what worked well, where persistent pressures remain, and what actions we need to prioritise going into next winter.

What steps he is taking to improve the recruitment and retention of staff in women’s health services.

Decisions about recruitment are a matter for individual National Health Service employers, who manage this at a local level to ensure they have the staff they need to deliver safe and effective care.The 10 Year Workforce Plan will ensure the NHS has the right people in the right places, with the right skills to care for patients, when they need it.As set out in the 10-Year Health Plan, the Government is committed to making the NHS the best place to work, by supporting and retaining our hardworking and dedicated healthcare professionals.To support this ambition, the Government plans to introduce a new set of standards for modern employment in April 2026. The new standards will reaffirm our commitment to improving retention by tackling the issues that matter to staff including promoting flexible working, improving staff health and wellbeing, and dealing with violence, racism, and sexual harassment in the NHS workplace. They will provide a framework for leaders across the NHS to build a supportive culture that embeds retention.

What steps he is taking to increase access to women's health hubs.

The Government is encouraging integrated care boards (ICBs) to further expand the coverage of women’s health hubs and supporting them to use the learning from the women’s health hub pilots to improve local delivery of services to women and girls.The 10-Year Health Plan set out our ambition for high autonomy to be the norm across every part of the country. ICBs are responsible for commissioning services that meet the healthcare needs of their local population and have the freedom to do so, and this includes women's health hubs and delivering the direction of the Women's Health Strategy. The Government is backing ICBs to do this through record funding. The 2025 Spending Review prioritised health, with record investment in the health and social care system.

What steps he is taking to tackle health inequalities impacting women.

The Government is committed to building a fairer Britain, to ensure people can live well for longer. Our reimagined National Health Service will tackle inequalities in both access and outcomes, as well as give everyone, no matter who they are or where they come from, the means to engage with the National Health Service on their own terms. This financial year the Department has invested approximately £53 million in direct research awards on research to support the health of women. This includes conditions that are unique to women, such as endometriosis, and health topics that are relevant to women such as violence and abuse.Significant progress has been made towards delivering the ambitions in the 2022 Women’s Health Strategy, for example improving women and girls’ awareness and access to services and driving research to benefit women’s health, but we know there is more to do.That is why we are renewing the Women’s Health Strategy, to assess the progress that has been made so far and to continue progressing delivery.The renewed strategy will update on the delivery of the 2022 Women’s Health Strategy and set out how the Government is taking further steps to improve women’s health as we deliver the 10-Year Health Plan. It will also address gaps from the 2022 strategy and drive further change on enduring challenges such as creating a system that listens to women and tackling health inequalities.

What assessment his Department has made of the potential impact of the junk food advertising ban on trends in the level of obesity.

Our manifesto commitment to restrict junk food TV advertising before 9pm, and online at all times, was a moral imperative. This measure is expected to remove around 7.2 billion calories from children’s diets each year and prevent 20,000 cases of childhood obesity. With this milestone achieved, we’re well on the way to raising the healthiest generation of children ever.

What data his Department holds on a) diagnosis and b) survival rates for glioblastoma.

Published Cancer Registration Statistics for England, including glioblastoma, are available at the following link: https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2023 Cancer mortality statistics for England for 2023 are also available at the following link: https://digital.nhs.uk/data-and-information/publications/statistical/cancer-registration-statistics/england-2023/cancer-mortality Alternately, these are combined in the National Disease Registration Service Cancer Incidence and Mortality interactive dashboard, which is available at the following link: https://nhsd-ndrs.shinyapps.io/incidence_and_mortality/

Whether he plans to introduce a data-driven system to (a) identify and (b) address disparities in the early diagnosis of cancer.

The Department remains committed to making improvements across different cancer types and to reducing disparities in cancer survival. Early cancer diagnosis is also a specific priority within the National Health Service’s wider Core20Plus5 approach to reducing healthcare inequalities.The National Disease Registration Service (NDRS) in NHS England is the cancer registry for England and collects data on the diagnosis and treatment of cancer patients. The data collected captures a patient’s complete journey from referral, diagnosis, treatment, outcomes, experience, and survival. The data collected is used to inform trends and monitor and detect changes in health and disease in the population, including disparities in diagnosis. NDRS’s strategic priorities focus on making data more timely and accessible, and better understanding health inequalities.Furthermore, the National Cancer Plan, to be published in the new year, will include further details on how we will use data to improve outcomes for cancer patients in England, including by driving earlier diagnosis and reducing the gap in early diagnosis between those living in the richest and poorest areas.

What steps the Department is taking to improve early identification and monitoring of precursor conditions for blood cancer, such as MGUS and smoldering myeloma.

It is a priority for the Government to support the National Health Service to diagnose blood cancer and precursor conditions as quickly as possible and to treat them faster, to improve outcomes.To improve diagnoses of blood cancers and precursor conditions, the NHS is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.The Government will get the NHS diagnosing blood cancers earlier and treating them faster, and will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners.The National Cancer Plan, which will be published in the new year, will include further details on how the NHS will improve outcomes for all cancer patients, including speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.

Whether his Department plans to increase research funding into new (a) tools and (b) other technologies for the earlier diagnosis of (i) pancreatic, (ii) lung, (iii) liver, (iv) stomach, (v) brain, (vi) oesophageal cancers and (vii) other the less survivable cancers.

The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR).An example of this is the NIHR investing £2.4 million into the miONCO-Dx trial, which seeks to develop a blood test designed to detect 12 different cancers, that could transform how cancer is diagnosed in the National Health Service.The NIHR is also funding a new artificial intelligence (AI) powered radiology analysis service, designed to develop and evaluate the use of AI in medical imaging to improve the detection of cancers, including for lung and brain tumours. The use of this technology will help to speed up response times and provide more accurate diagnoses and better-targeted treatments, ultimately improving outcomes for patients.The NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancers. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.

What steps his Department is taking to improve access to innovative treatments for people with SOD1 motor neurone disease.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the Naitonal Health Service on whether new medicines represent a clinically and cost-effective use of resources. NICE aims, wherever possible, to issue guidance close to the time of licensing, and the NHS in England is legally required to fund medicines recommended by NICE, normally within three months of the publication of final guidance.NICE has selected tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations as a topic for guidance development through its Highly Specialised Technology (HST) programme. The HST programme appraises medicines for the treatment of very rare, and often very severe diseases, and evaluates whether they can be considered a clinically and cost-effective use of NHS resources. NICE is working with the company to confirm timelines for this evaluation.

What assessment his Department has made of (a) the distances travelled and (b) costs incurred by children and young people travelling to principle treatment centres in London; and what assessment he has made of the potential the merits of introducing a young cancer patient travel fund.

The Department of Health and Social Care knows that the cost of travel is an important issue for many young cancer patients and their families in England. NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of their local communities are met, including providing support for travel.The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests, when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or a Personal Independence Payment. There are also several charities in the United Kingdom who provide support, including financial support, for patients with cancer.On 4 February 2025, the Department of Health and Social Care relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for young cancer patients. The work of the taskforce is ongoing, and officials are exploring opportunities for improvement across a range of areas, including detection and diagnosis, genomic testing and treatment, research and innovation, and patient experience. The taskforce will also ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan, which will include further details on how we will improve outcomes for children and young people with cancer in England.The Department of Health and Social Care has not made a formal assessment of costs incurred by children and young people travelling to Principal Treatment Centres in London, the trends in levels of travel costs and the impact of this on young cancer patients missing appointments and delaying treatment. Young Lives vs Cancer is a valued stakeholder with a unique perspective on the issue of travel support for children and young people with cancer. The Department of Health and Social Care will continue to engage with Young Lives vs Cancer, as well as other children and young people cancer charity stakeholders as we progress this important work.

With reference to Young Lives vs Cancer's report entitled A young cancer patient travel fund, published in February 2024, whether his Department has made an assessment of (a) trends in levels of travel costs, (b) the adequacy of the amount of financial support for young cancer patients and their families and (b) the potential impact on (i) missing appointments and (ii) delaying treatment.

The Department of Health and Social Care knows that the cost of travel is an important issue for many young cancer patients and their families in England. NHS England and the integrated care boards are responsible for commissioning and ensuring the healthcare needs of their local communities are met, including providing support for travel.The National Health Service in England runs the Healthcare Travel Costs Scheme (HTCS) to provide financial assistance for travel to a hospital or other NHS premises for specialist NHS treatment or diagnostics tests, when referred by a doctor or other primary healthcare professional. Patients who do not qualify for the HTCS and who are on a low income may be able to claim the costs from the Department for Work and Pensions through Universal Credit or a Personal Independence Payment. There are also several charities in the United Kingdom who provide support, including financial support, for patients with cancer.On 4 February 2025, the Department of Health and Social Care relaunched the Children and Young People Cancer Taskforce to identify tangible ways to improve outcomes and experiences for young cancer patients. The work of the taskforce is ongoing, and officials are exploring opportunities for improvement across a range of areas, including detection and diagnosis, genomic testing and treatment, research and innovation, and patient experience. The taskforce will also ensure that the unique needs of children and young people with cancer are carefully considered as part of the National Cancer Plan, which will include further details on how we will improve outcomes for children and young people with cancer in England.The Department of Health and Social Care has not made a formal assessment of costs incurred by children and young people travelling to Principal Treatment Centres in London, the trends in levels of travel costs and the impact of this on young cancer patients missing appointments and delaying treatment. Young Lives vs Cancer is a valued stakeholder with a unique perspective on the issue of travel support for children and young people with cancer. The Department of Health and Social Care will continue to engage with Young Lives vs Cancer, as well as other children and young people cancer charity stakeholders as we progress this important work.

What steps his Department is taking to help reduce variations in access to treatments approved by the National Institute for Health and Care Excellence for advanced and complex Parkinson’s Disease.

We have delivered an additional two million appointments in England, seven months ahead of schedule. This includes operations, consultations, diagnostic tests, and treatments. These additional appointments have taken place across a number of specialities, including neurology.We have launched a 10-Year Health Plan to reform the National Health Service. The plan will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention. A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients, including for those with Parkinson’s, across our communities.There are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme (NTP).The GIRFT National Specialty Report made recommendations designed to improve services nationally and to support the NHS to deliver care more equitably across the country. The report highlighted differences in how services are delivered, and provided the opportunity to share successful initiatives between trusts to improve patient services nationally. In addition, the NTP has developed a model of integrated care for neurology services to support integrated care boards (ICBs) to deliver the right service, at the right time for all neurology patients, which includes providing care closer to home.Once diagnosed, and with a management strategy in place, the majority of people with Parkinson’s can be cared for through routine access to primary and secondary care. NHS England commissions the specialised elements of Parkinson’s care that patients may receive from 27 neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals, including Parkinson’s disease nurses, psychologists, and allied health professionals such as dieticians and speech and language therapists, and that they can receive specialised treatment and support, according to their needs.In addition, in February 2024, a new treatment for advanced-stage Parkinson’s, foslevodopa–foscarbidopa, was rolled out in the NHS. It has been shown to improve motor function, with patients experiencing longer periods of time without dyskinesia.The NHS in England is legally required to make funding available for treatments recommended in National Institute for Health and Care Excellence (NICE) technology appraisal guidance. If there are any concerns with the availability of a NICE-recommended treatment in a particular area, they should be raised with the local ICB in the first instance.

What steps his Department is taking within current NHS workforce planning to improve uptake of digital consultations for Parkinson’s patients as a mechanism to reduce neurology waiting times and reduce the backlog in accessing a neurologist.

We have delivered an additional two million appointments, seven months ahead of schedule. This includes operations, consultations, diagnostic tests, and treatments. These additional appointments have taken place across a number of specialities, including neurology.Whilst no specific assessment has been made of how workforce shortages are impacting the delivery of care, there are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme.We have launched a 10-Year Health Plan to reform the National Health Service. The plan will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention.A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients across our communities.

What steps his Department plans to take to ensure that Parkinson’s Disease services across England are supported to provide the full range of NICE-approved treatment options to eligible patients in a timely manner.

We have delivered an additional two million appointments in England, seven months ahead of schedule. This includes operations, consultations, diagnostic tests, and treatments. These additional appointments have taken place across a number of specialities, including neurology.We have launched a 10-Year Health Plan to reform the National Health Service. The plan will set out a bold agenda to deliver on the three big shifts needed, to move healthcare from hospital to the community, from analogue to digital, and from treatment to prevention. A central and core part of the 10-Year Health Plan will be our workforce and how we ensure we train and provide the staff, technology, and infrastructure the NHS needs to care for patients, including for those with Parkinson’s, across our communities.There are a number of initiatives supporting service improvement and better care for patients with Parkinson’s disease in England, including the Getting It Right First Time (GIRFT) Programme for Neurology, the RightCare Progressive Neurological Conditions Toolkit, and the Neurology Transformation Programme (NTP).The GIRFT National Specialty Report made recommendations designed to improve services nationally and to support the NHS to deliver care more equitably across the country. The report highlighted differences in how services are delivered, and provided the opportunity to share successful initiatives between trusts to improve patient services nationally. In addition, the NTP has developed a model of integrated care for neurology services to support integrated care boards (ICBs) to deliver the right service, at the right time for all neurology patients, which includes providing care closer to home.Once diagnosed, and with a management strategy in place, the majority of people with Parkinson’s can be cared for through routine access to primary and secondary care. NHS England commissions the specialised elements of Parkinson’s care that patients may receive from 27 neurology centres across England. Within these specialised centres, neurological multidisciplinary teams ensure patients can access a range of health professionals, including Parkinson’s disease nurses, psychologists, and allied health professionals such as dieticians and speech and language therapists, and that they can receive specialised treatment and support, according to their needs.In addition, in February 2024, a new treatment for advanced-stage Parkinson’s, foslevodopa–foscarbidopa, was rolled out in the NHS. It has been shown to improve motor function, with patients experiencing longer periods of time without dyskinesia.The NHS in England is legally required to make funding available for treatments recommended in National Institute for Health and Care Excellence (NICE) technology appraisal guidance. If there are any concerns with the availability of a NICE-recommended treatment in a particular area, they should be raised with the local ICB in the first instance.